This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Meiji Seika Pharma Co., Ltd.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Toshiaki Nagasato: Innovator in Biotechnological Advancements
Introduction
Toshiaki Nagasato is a prominent inventor based in Odawara, Japan. He has made significant contributions to the field of biotechnology, particularly in the production of recombinant proteins. His innovative work has implications for various applications in medicine and research.
Latest Patents
Nagasato holds a patent for a method of producing horseradish peroxidase recombinant protein using filamentous fungus. The patent describes a modified polynucleotide that has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon corresponds to the codon usage frequencies of three filamentous fungal species. This polynucleotide is capable of expressing the polypeptide in a filamentous fungus, showcasing Nagasato's innovative approach to protein production.
Career Highlights
Nagasato is associated with Meiji Seika Pharma Co., Ltd., where he continues to advance his research and development efforts. His work has not only contributed to the scientific community but has also enhanced the capabilities of his company in the biopharmaceutical sector.
Collaborations
Nagasato has collaborated with notable colleagues, including Fumikazu Yokoyama and Kaoru Okakura. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Toshiaki Nagasato's contributions to biotechnology, particularly through his patented methods, highlight his role as an influential inventor. His work continues to pave the way for advancements in recombinant protein production, benefiting both the scientific community and the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
